Prediction of liver disease in patients whose liver function tests have been checked in primary care: Model development and validation using population-based observational cohorts

BMJ Open

Volumn 4, Issue 6, 2014, Pages

  McLernon, David J ^a   Donnan, Peter T ^b   Sullivan, Frank M ^c   Roderick, Paul ^d   Rosenberg, William M ^e   Ryder, Steve D ^f   Dillon, John F ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREDICTION; PREDICTIVE VALUE; PRESCRIPTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY MEDICAL CARE; SCORING SYSTEM; SECONDARY HEALTH CARE; UNITED KINGDOM; VALIDATION STUDY; LIVER DISEASES; MIDDLE AGED; PRIMARY HEALTH CARE; RISK ASSESSMENT; SCOTLAND; STATISTICAL MODEL;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; RISK ASSESSMENT; SCOTLAND;

EID: 84901913803     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-004837     Document Type: Article

References (39)

1. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
2. Schalk BW, Visser M, Bremmer MA, et al. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol 2006;164:969-77.
3. Sorensen HT, Moller-Petersen JF, Felding P, et al. Epidemiology of abnormal liver function tests in general practice in a defined population in Denmark. Dan Med Bull 1991;38:420-2.
4. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983-6.
5. Roderick P. Commentary: liver function tests: defining what's normal. BMJ 2004;328:987.
6. Sherwood P, Lyburn I, Brown S, et al. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001;322:276-8.
7. McLernon DJ, Donnan PT, Ryder S, et al. Health outcomes following liver function testing in primary care: a retrospective cohort study. Fam Pract 2009;26:251-9.
8. Moons K, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ 2009;338:b375.
9. Fornasini M, Brotons C, Sellarès J, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract 2006;23:28-33.
10. Siris ES, Baim S, Nattiv A. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Postgrad Med 2010;122:82-90.
11. Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009;338:b605.
12. Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess 2009;13:iii-iv, ix-xi, 1-134.
13. Carstairs V, Morris R. Deprivation and mortality: an alternative to social class? Community Med 1989;11:210-19.
14. Evans JM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999;47:105-10.
15. NHS National Services Scotland. SMR01 - General/Acute Inpatient and Day Case. http://www.datadictionary.scot.nhs.uk/isddd/9065.html
16. Morris AD, Boyle DI, MacAlpine R, et al. The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register. BMJ 1997;15:524-8.
17. Donnan PT, Wei L, Steinke DT, et al. Presence of bacteriuria caused by trimethoprium resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data. BMJ 2004;328:1297-301.
18. Steinke DT, Weston TL, Morris AD, et al. The epidemiology of liver disease in Tayside database: a population-based record-linkage study. J Biomed Inform 2003;35:186-93.
19. Collett D. Modelling survival data in medical research. 2nd edn. Boca Raton: Chapman & Hall/CRC, 2003.
20. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92.
21. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
22. Yuan YC. Multiple imputation for missing data: concepts and new development. SUGI Proceedings, 2000 Rockville, MD: SAS Institute Inc. http://support.sas.com/rnd/app/papers/multipleimputation.pdf
23. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011;30:22-38.
24. University of Aberdeen. Primary Care Clinical Informatics Unit. http://www.abdn.ac.uk/pcciu/index.htm
25. Information Services Division Scotland. General practice - Practice Team Information (PTI). http://www.isdscotland.org/isd/1283.html#Background-to-PTI
26. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23.
27. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer, 2009.
28. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565.
29. Sullivan LM, Massaro JM, D 'Agostino RB Sr. Tutorial in biostatistics: presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004;23:1631-60.
30. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014. http://www.R-project.org
31. Vickers AJ. Memorial Sloan Kettering Cancer Centre: Epidemiology and Biostatistics: Decision curve analysis. http://www.mskcc.org/research/ epidemiology-biostatistics/health-outcomes/decision-curve-analysis-0
32. Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008;8:53.
33. McLernon DJ, Dillon JF, Sullivan FM, et al. The utility of liver function tests for mortality prediction within one year in primary care using the Algorithm for Liver Function Investigations (ALFI). PLoS ONE 2012;7:e50965.
34. Dorans K. Pilot projects aim to ease access to clinical data. Nat Med 2009;15:226.
35. D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham Coronary Heart Disease Prediction Scores. Results of a multiple ethic groups investigation. JAMA 2001;286:180-7.
36. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
37. Hawkins RC. The evidence based medicine approach to diagnostic testing: practicalities and limitations. Clin Biochem Rev 2005;26:7-18.
38. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655.
39. Goodwin N. Diagnostic delays and referral management schemes: how 'integrated' primary care might damage your health. Int J Integr Care 2008;8:e78.